Bicara Therapeutics (BCAX) grants 38,950 stock options to director
Rhea-AI Filing Summary
Bicara Therapeutics director Jeremy Bender reported an equity compensation award in the form of a Stock Option (Right to Buy) covering 38,950 shares of common stock. The option has an exercise price of $26.88 per share and expires on July 28, 2036. One-third of the shares underlying the option vest and become exercisable on July 28, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to his continued service on each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bender Jeremy
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 38,950 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 38,950 shares (Direct)
Footnotes (1)
- F1. One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Stock options granted: 38,950 shares
Exercise price: $26.88 per share
Option expiration date: 2036-07-28
+1 more
4 metrics
Stock options granted
38,950 shares
Grant of Stock Option (Right to Buy) on 2026-07-28 to a director
Exercise price
$26.88 per share
Conversion or exercise price of the stock option
Option expiration date
2036-07-28
Expiration date of the Stock Option (Right to Buy)
Initial vesting date
July 28, 2027
One-third of the shares underlying this option vest and become exercisable on this date
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vest and become exercisable
4 terms
Stock Option (Right to Buy) financial
"Security title reported as Stock Option (Right to Buy) for the award"
exercise price financial
"Conversion or exercise price of $26.8800 per share for the option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The option carries an expiration date of 2036-07-28"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest and become exercisable financial
"One-third of the shares underlying this option shall vest and become exercisable on July 28, 2027"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did Jeremy Bender report for BCAX?
Jeremy Bender reported a grant of stock options for 38,950 shares of Bicara Therapeutics common stock. These options carry a $26.88 exercise price, vest over time starting in 2027, and represent equity-based compensation for his role as a director.
How many stock options were granted to Jeremy Bender in this BCAX filing?
The filing reports a grant of 38,950 stock options to director Jeremy Bender. Each option relates to one share of Bicara Therapeutics common stock, providing potential future ownership if exercised once the options have vested and are in-the-money.
What is the exercise price and expiration date of Bender's BCAX options?
The options have an exercise price of $26.88 per share and an expiration date of July 28, 2036. This means Bender may purchase shares at $26.88, once vested, any time before the option term ends in 2036.
How do the stock options for BCAX vest for Jeremy Bender?
The options vest in stages: one-third of the underlying shares vest and become exercisable on July 28, 2027. The remaining shares vest in 24 equal monthly installments after that date, conditioned on Bender’s continued service on each vesting date.
Was the BCAX insider transaction reported under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not selected, so this grant is not reported as made under a pre-arranged Rule 10b5-1 trading plan. It is presented simply as an equity award to a director.